.jpg?1685413069)
The 1st International Electronic Conference on Metabolomics
Part of the International Electronic Conference on Metabolism and Metabolomics series
1–30 Nov 2016
- Go to the Sessions
- Event Details
Welcome from the Chair
Welcome from the Chair of the 1st International Electronic Conference of Metabolomics (IECM-1)
Metabolites (www.mdpi.com/journal/metabolites), a peer-reviewed, scientific
journal, edited by MDPI AG, is proud to be the organizer and sponsor of this first International Electronic Conference on Metabolomics. Contributions dealing with any discipline promoting metabolism and metabolomics will be considered.
The conference will be held online (www.sciforum.net/conference/iecm-1) from 1–30 November 2016, enabling you to present your latest research to the scientific community and to have the opportunity to participate in fruitful exchanges with academic and industrial groups from around the world. Participation, as an author or a visitor, is ABSOLUTELY FREE of charge (simply create an account on the home page). Proceedings from the conference (abstracts) will be published after the event in the online open access journal, Metabolites.
On behalf of our active scientific committee and dynamic editorial staff, we warmly invite you to join us at this first International Electronic Conference on Metabolomics and we look forward to posting your contribution.
Sincerely yours,
A/Prof. Peter J Meikle
Chair of the 1st International Electronic Conference on Metabolomics
Editor-in-chief of Metabolites (ISSN 2218-1989)
NHMRC Senior Research Fellow Program Head, Metabolism
Head, Metabolomics Laboratory
Baker IDI Heart and Diabetes Institute
75 Commercial Road, Melbourne VIC 3004, Australia
E-Mail: [email protected]
Website: www.bakeridi.edu.au
A/Prof Peter Meikle is a NHMRC Senior Research Fellow, Program leader for Metabolism and Head of the Metabolomics Laboratory within Baker IDI Heart and Diabetes Institute. He is Editor-in-Chief of Metabolites and holds affiliate positions at the University of Melbourne, Monash University and the University of Sydney. The Metabolomics Laboratory has a focus on the dyslipidemia and altered lipid metabolism associated with obesity, diabetes and cardiovascular disease and its relationship to the pathogenesis of these disease states. This work is leading to new approaches to early diagnosis and risk assessment as well as the development of new lipid modulating therapies for chronic disease.
Call for Papers
- Section A
Metabolomics in Human Diseases: Clinical applications of metabolomics,including but not limited to: understanding metabolic diseases, biomarker discovery,inborn errors of metabolism,heart disease,and cancer metabolism/metabolomics - Section B
Applications of Metabolomics in Agriculture and Industry: Plant metabolomics, microbial metabolomics,nutritional metabolomics, plant-pathogen interaction metabolomics, identification of toxins and pollutants, effects of genetic and environmental perturbations on metabolite levels and fluxes - Section C
Analytic Techniques in Metabolomics: Progress in methods for biological sample preparation, metabolite identification, structure elucidation and quantification, advances in metabolomic data processing, analysis and curation - Section D
Metabolomics Modeling: Experimental and computational advances in the analysis of metabolic flux; metabolic processes analysis and modelling; quantitative metabolomics application in metabolism modelling; computational modelling of metabolic networks; computational analysis of the effects of genetic and nutritional modification on cell metabolism and growth.
Conference Chairs
[email protected]
Instructions for Authors
Submissions should be done by the authors online by registering with www.sciforum.net, and using the "Start New Submission" function once logged into system.
Researchers interested in attending the conference must submit the abstract, on this website and no later than 25 September 2016.
After the abstract is accepted by the Scientific Committee by 30 September 2016, the authors will be invited to prepare a full description of their work preferably under the form of a PowerPoint presentation, and to upload it before 20 October 2016 to ensure final check.
The presentations will be accessible on https://www.sciforum.net/conference/iecm-1 during the conference time.
Authors are encouraged to prepare a power point presentation using the template provided by the Conference. Slides will be displayed directly in the website using Sciforum.net's proprietary slides viewer. They can be prepared in the same way as for any traditional conference where research results can be presented. Slides should be converted to the PDF format before submission so that our process can easily and automatically convert them for online displaying.
International Electronic Conference on Metabolomics PPT template file
The following organization is recommended for your presentation:
- Title,Full author names,Affiliations, email address of the corresponding author, Logo of the institution
- Graphical Abstract
- Abstract (max 200 words) and 3-5 Keywords
- Introduction
- Results and Discussion
- Conclusions
- Acknowledgements, funding
MDPI AG, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their research works. Hence, by submitting a contribution to this conference, the authors retain the copyright of their contribution, but they grant MDPI AG the non-exclusive right to publish this contribution online on the Sciforum.net platform. This means the authors can easily submit their contribution to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
List of accepted submissions (18)
Id | Title | Authors | Presentation | ||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-008957 | Metabolic Investigations of Molecular Mechanisms Associated with Parkinson’s Disease. | , , , , , , , , , , , , , , , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by fibrillar cytoplasmic aggregates of α-synuclein (i.e., Lewy bodies [LB]) and the associated loss of dopaminergic cells in the substantia nigra. But, mutations in genes such as α-synuclein (SNCA) account for only 10% of PD occurrences. The exposure to environmental toxicants including pesticides (e.g. paraquat [PQ]) and manganese (Mn), are also recognized as important PD risk factors. Thus, aging, genetic alterations and environmental factors all contribute to the etiology of PD. In fact, both genetic and environmental factors are thought to interact in the promotion of idiopathic PD, but the mechanisms involved are still unclear. In this study, we report a toxic synergistic effect between α-synuclein and either paraquat or Mn treatment. We identified an essential role for central carbon (glucose) metabolism in dopaminergic cell death induced by paraquat or Mn treatment that is enhanced by the overexpression of α-synuclein. PQ “hijacks” the pentose phosphate pathway (PPP) to increase NADPH reducing equivalents and stimulate paraquat redox cycling, oxidative stress, and cell death. PQ also stimulated an increase in glucose uptake, the translocation of glucose transporters to the plasma membrane, and AMPK activation. The overexpression of α-synuclein further stimulated an increase in glucose uptake and AMPK activity, but impaired glucose metabolism. In effect, α-synuclein activity directs additional carbon to the PPP to supply paraquat redox cycling. Alternatively, Mn induces an upregulation in glycolysis and the malate-aspartate shuttle to compensate for energy depletion due to Mn toxicity. Mn treatment causes a decrease in carbon flow through the TCA cycle and a disruption in pyruvate metabolism, which are consistent with a dysfunctional mitochondria and inhibition of pyruvate dehydrogenase. The overexpression of α-synuclein was shown to potentiate Mn toxicity by glycolysis impairment by inhibiting aldolase activity. In effect, α-synuclein overexpression negates the metabolic response to alleviate Mn toxicity that results in an increase in cell death. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-008812 | Identification of metabolic changes in dementia patients using FTIR | , , , , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Alzheimer’s disease diagnosis is mainly based in the identification of the cognitive disorder in patients who have already overt the advanced stage of dementia, when is too late for some kind of therapeutic adjustment. Therefore, in order to improve early recognition of Alzheimer’s disease, novel approaches for biomarkers identification, such as metabolomics, are been developed and the potential of Fourier Transform Infrared Spectroscopy (FTIR) in the clinical field is receiving particular attention. The present work aims to contribute to identification of the main pathological changes that occurred during neurodegeneration, by identifying plasma biochemical alterations that might be related to dementia and discriminate control from cognitive impaired samples, through FTIR analysis. Multivariate analysis was applied to spectra data (n=45). Plasma samples from cognitive impaired subjects presented a higher content of saturated lipids in relation to the unsaturated ones, which translates in high potential brain damage. It was also noticed the presence of carboxylic acids (usually related to lipid hyperoxidation), production of reactive carbonyls, and proteins structural and functional alterations. Differences in protein conformation were also identified between control and disease samples and were mainly related with occurrence of protein aggregates.Some changes were also associated with oxidative cellular damage in disease samples. In conclusion, FTIR has potential to be applied in future not only for cognitive impairment diagnosis but also for identification of disease stage and prognostic evaluation, besides assessment of disease developing risk for control subjects.
|
|||||||||||||||||||||||||||||||||||||||||
sciforum-008508 | Metabolomic fingerprinting of serum samples by direct infusion mass spectrometry |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||||
Metabolomics has demonstrated a great potential in numerous biomedical research fields in the last years, such as the study of the underlying pathology of diseases, discovery of diagnostic biomarkers or drug development. Nowadays, the main challenge in metabolomics is to obtain comprehensive and unbiased metabolomic profiles due to the huge complexity, heterogeneity and dynamism of metabolome. For this purpose, mass spectrometry represents a very interesting analytical platform, since complexity of metabolome may be overcome through the use of different orthogonal separation techniques, including liquid chromatography, gas chromatography and capillary electrophoresis. Alternatively, direct mass spectrometry analysis, either by direct infusion or flow injection, has been postulated as an alternative in metabolomics, complementing hyphenated approaches. These techniques exhibit several advantages such as the ability for high-throughput screening, fast analysis and wide metabolomic coverage, since there is not exclusion of compounds due to the separation device. The present work explores the potential of metabolomic platforms based on direct infusion mass spectrometry for metabolic fingerprinting of serum samples. The most important issues to be considered in this type of approaches were reviewed, including sample handling, comprehensive analysis, data processing, as well as further identification of metabolites and global characterization of metabolomic fingerprints. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-008973 | Metabolomic to target insecticidal compounds of Caesalpinia pluviosa var. peltophoroides against Spodoptera frugiperda | , , , , , , , |
![]() |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Introduction Spodoptera frugiperda (Lepidoptera: Noctuidae) is one of the main plagues of maize cultivation and it is resistant to the most used insecticides. Plants are important source of biopesticides due to their own mechanisms of interaction and diversified composition. Thus, fractions (hexane, acetate and hydro-ethanol ) of extracts from different parts of Caesalpinia pluviosa var. peltophoroides (Fabaceae) have insecticidal activity investigated. Chemical composition of the fractions were evaluated by UHPLC-HRFTMS, thereafter processed on MZmine 2.2 software and exported to do multivariate statistical analysis (MSA) - O2PLS-DA (SIMCA-P 13.0). The dereplication of compounds were performed using DNP© , Scifinder® and our in house Caesalpinia database. Results and Discussion Six fractions were inactive and five displayed pupal or larval mortality. The O2PLS-DA analysis found a clear separation of inactive and insecticidal group (R2= 0,72) and indicated the metabolites highly correlated with the insecticidal property (VIP>1.95): eugenyl vicianoside; gluconic acid lactone and gallic acid. Conclusions Thus, through metabolomic strategies was possible to dereplicate the compounds most correlated with insecticidal property and this knowledge can be very useful to development of new techniques to the crop pest control. Acknowledgements FAPEMIG and CNPQ for the financial funding and the AsterBioChem for the UHPLC-HRMS analysis. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-007908 | Clinical Metabolomics: Analytical Tool for Drug Development. |
![]() |
Show Abstract |
||||||||||||||||||||||||||||||||||||||
It is recognized that altered metabolic states reports on the chronic and acute disease statuses. Decades of research have shown that metabolism is not a self-regulating network operating independently but rather heavily integrated into every cellular process and involved in organ system functions. Therefore global monitoring of metabolic processes is recommended for more comprehensive understanding of the initiation and advancement of disease. Mass spectrometry based metabolomics, in particular, demonstrates tremendous promise in delivering high throughput quantitative information on alterations in metabolism associated with disease onset/progression and response to pharmaceutical intervention. Recent advances in mass spectrometry and informatics tools have facilitated emerging in house OMICS platforms capable of translating biological output into viable therapeutic candidates and assist in stratifying patient populations. At BERG, we have implemented an industrial level high throughput metabolomics platform providing both high quality and depth of information allowing for reliable and broadest capture of the metabolome for the pre-clinical and clinical matrixes analyzed. Global metabolomics platform dedicated for theranostic and clinical studies as well as tracer metabolomics are harvested to facilitate CDx biomarkers discovery in a unique way. Highlights of the BERG’s in-depth patient stratification approaches as well as biology based drugs will be presented. |
Contact Information
Ms. Jely He
[email protected]
Metabolites Editorial Office
[email protected]
Conference Schedule
- Deadline for Abstract Submission: 15 September 2016 25 September 2016
- Notification of Acceptance: 30 September 2016
- PowerPoint Presentation Submission: 20 October 2016
Conference Organizers
Dr. Peter Meikle
Metabolomics Laboratory, Baker IDI Heart and Diabetes Institute,
Melbourne, Victoria 3004, Australia
Editor-in-Chief of Metabolites
Scientific Advisory Committee
Prof. Dr. Daniel Raftery, University of Washington, USA
Dr. Miroslava Cuperlovic-Culf, National Research Council of Canada, Canada
Prof. Dr. James Cox, University of Utah, USA
Dr. Katja Dettmer, University of Regensburg, Germany
Dr. Adrian S. Culf, Sussex Research Laboratories, Canada
Organizing Committee
Dr. Shu-Kun Lin, MDPI AG, Basel, Switzerland
Ms. Jely He, MDPI Branch Office, Wuhan
Contact Information
List of Keynotes & Videos
Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis
A. Metabolomics in Human Diseases
Clinical applications of metabolomics,including but not limited to: understanding metabolic diseases, biomarker discovery,inborn errors of metabolism,heart disease,and cancer metabolism/metabolomics.
This section is chaired by:
Prof. Dr. Daniel Raftery, Department of Anesthesiology & Pain Medicine, School of Medicine, University of Washington, Seattle, USA
Session Chair
Professor Daniel Raftery, University of Washington
B. Applications of Metabolomics in Agriculture and Industry
Plant metabolomics, microbial metabolomics,nutritional metabolomics, plant-pathogen interaction metabolomics, identification of toxins and pollutants, effects of genetic and environmental perturbations on metabolite levels and fluxes
This section is chaired by:
Prof. Dr. James Cox, University of Utah, USA
Dr. Katja Dettmer, University of Regensburg, Germany
Session Chairs
Dr. James Cox
Professor Katja Dettmer
Show all published submissions (4) Hide published submissions (4)
Submissions
List of Papers (4) Toggle list
C. Analytic Techniques in Metabolomics
Progress in methods for biological sample preparation, metabolite identification, structure elucidation and quantification, advances in metabolomic data processing, analysis and curation
This Section is chaired by:
Dr. Adrian S. Culf, Sussex Research Laboratories, Canada
Session Chair
Dr. Adrian S. Culf
Show all published submissions (7) Hide published submissions (7)
Submissions
List of Papers (7) Toggle list
D. Metabolomics Modeling
Experimental and computational advances in the analysis of metabolic flux; metabolic processes analysis and modelling; quantitative metabolomics application in metabolism modelling; computational modelling of metabolic networks; computational analysis of the effects of genetic and nutritional modification on cell metabolism and growth.
This section is chaired by:
Dr. Miroslava Cuperlovic-Culf, National Research Council of Canada, Canada
Session Chair
Dr. Miroslava Cuperlovic-Culf
Show all published submissions (1) Hide published submissions (1)
Submissions
List of Papers (1) Toggle list